Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Berzelius made some initial characterisations of the new metal and its chemical compounds: he correctly determined that the thorium–oxygen mass ratio of thorium oxide was 7.5 (its actual value is close to that, ~7.3), but he assumed the new element was divalent rather than tetravalent, and so calculated that the atomic mass was 7.5 times that of oxygen (120 Da); it is actually 15 times as large. He determined that thorium was a very electropositive metal, ahead of cerium and behind zirconium in electropositivity. Metallic thorium was isolated for the first time in 1914 by Dutch entrepreneurs Dirk Lely Jr. and Lodewijk Hamburger.
=== Increases in federal funding === On June 17, 1971, Nixon held a press conference in which he announced, "America's public enemy number one in the United States is drug abuse." He continued, "In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive." In the speech, Nixon called for Congress to approve the allocation of $150 million in new funding to the "treatment and prevention of drug abuse." According to the Bureau of Labor Statistics, that is now the equivalent of just under $966 million.
This article records new taxa of fossil mammals of every kind that are scheduled to be described during the year 2026, as well as other significant discoveries and events related to paleontology of mammals that are scheduled to occur in the year 2026.
Connective tissue disorders predispose women to developing cystocele and other pelvic organ prolapses. The tissues tensile strength of the vaginal wall decreases when the structure of the collagen fibers change and become weaker.
Anaerobic respiration is respiration using electron acceptors other than molecular oxygen (O2) in its electron transport chain. In aerobic organisms, electrons are shuttled to an electron transport chain, and the final electron acceptor is oxygen. Molecular oxygen is an excellent electron acceptor. Anaerobes instead use less-oxidizing (in either thermodynamic or kinetics sense) substances such as nitrate (NO−3), fumarate (C4H2O2−4), sulfate (SO2−4), or elemental sulfur (S), among others. These terminal electron acceptors have smaller reduction potentials than O2. Less energy per oxidized molecule is released. Therefore, anaerobic respiration is less efficient than aerobic.
Sources: en.wikipedia.org
1,8-Cineole 2-exo-monooxygenase (EC 1.14.14.56, CYP3A4) is an enzyme with systematic name 1,8-cineole,NADPH:oxygen oxidoreductase (2-exo-hydroxylating). This enzyme catalyses the following chemical reaction
=== Response to pollution and environmental stress === Historical records indicate that X. parietina persisted in London despite severe air pollution, even when many other lichens disappeared. Mid-20th century mapping studies revealed that its distribution correlated with areas of moderate sulphur dioxide concentrations, but it was absent from the most polluted zones of central London, suggesting that while resistant to airborne contaminants, it has an upper tolerance limit. However, it is sensitive to certain pollutants, as demonstrated after the Torrey Canyon oil spill, when oil contamination and toxic dispersants caused widespread mortality on coastal rocks. Affected thalli lost their characteristic orange pigmentation, indicating chemical damage that interfered with enzymatic and protein activity, ultimately leading to detachment from the rock surface. The dispersant BP 1002, used during cleanup efforts, was later found to be highly toxic to marine life and coastal lichens. In X. parietina, its surfactant components disrupted algal cell membranes, reducing photosynthetic activity and accelerating thallus deterioration. Pollution affects both the population structure and development of X. parietina. There has been a decline in population density with increasing pollution levels; one study documented approximately 47 thalli per tree in lightly polluted zones, compared to 12 in moderately polluted areas and 9 in severely polluted regions. In unpolluted environments, the lichen completes its full life cycle, reaching maturity and old age.
== Education and training == Verdine received a Bachelor of Science in chemistry from Saint Joseph's University and a PhD in chemistry from Columbia University, working under Koji Nakanishi and Maria Tomasz. He held an NIH postdoctoral fellowship in molecular biology at MIT and Harvard Medical School, and joined the faculty of Harvard University in 1988.
The agreement specified that this agreement was only with Amat-Mamu, and no other person could lay claim to Belessunu's estate by providing for her. Two years after the agreement was made, two of Belessunu's cousins and fellow nadītus—Amat-Šamaš and Nīši-īnīšu—laid claim to the fields. The mayor of Sippar, Zimri-Erah, ruled that the inheritance was rightfully Belessunu's. The cousins were penalized for making a false claim over property, and they were forced to give Amat-Mamu a tablet that relinquished their claims. Professor Rivkah Harris speculated that Belessunu passed over her cousins in favor of Amat-Mamu because Amat-Mamu was a member of a wealthy family and therefore better able to support Belessunu during her life.
According to a study by the World Health Organization (WHO), between 15% and 71% of women have already been victims of domestic violence, whether physical, sexual, or psychological. In France, a partner kills his wife more than once every two days, more often by deliberate homicide than by violence resulting in death. Measures implemented to combat violence against women include government intervention as well as that of the Ministry of Education. Numerous awareness campaigns have been established in schools. The Ministry of the Interior enacted a law on March 23, 2006, to promote gender equality in education. Several associations also intervene and advocate for gender diversity.
Sources: en.wikipedia.org
==== Fake news about the alleged "Taxation of Pix" ==== At the beginning of January 2025, a regulation (IN RFB No. 2219/2024) entered into force, which changed the way the Federal Revenue of Brazil monitors transactions via Pix and credit card in order to reinforce the fight against illicit operations. With this measure, all financial institutions, including digital banks and payment apps, became obliged to report monthly movements above 5,000 reais for individuals and 15,000 for companies. The Revenue Service stressed that financial transactions would not suffer increases in taxes, only that they would be subject to additional inspection to monitor atypical movements, such as the non-declaration of income tax by individuals who move more than 5,000 reais monthly. Since 2003, financial monitoring has been carried out through Decred (current e-Financeira), the Revenue Service system that tracks transactions made with credit cards. With the regulation that entered into force in 2025, monitoring was expanded to include transactions via Pix, sales made through card readers, payments with debit cards, store cards and virtual currencies, movements that would be reported to the Federal Revenue Service. However, with the beginning of the inspection, fake news about the alleged taxation of Pix began circulating on social media. According to the false information, the Federal Revenue Service would create or increase taxation on the system, which would lead companies to pass on the costs to consumers.
== Unique characteristics == Like D-Peptides and β peptides, peptoids are completely resistant to proteolysis, and are therefore advantageous for therapeutic applications where proteolysis is a major issue. Since secondary structure in peptoids does not involve hydrogen bonding, it is not typically denatured by solvent, temperature, or chemical denaturants such as urea (see details below). Notably, since the amino portion of the amino acid results from the use of any amine, thousands of commercially available amines can be used to generate unprecedented chemical diversity at each position at costs far lower than would be required for similar peptides or peptidomimetics. To date, at least 230 different amines have been used as side chains in peptoids.
As for second-hand smoke, the NIH study points to the large amount of smoke generated by one cigar, saying "cigars can contribute substantial amounts of tobacco smoke to the indoor environment; and, when large numbers of cigar smokers congregate in a cigar smoking event, the amount of passive smoke produced is sufficient to be a health concern for those regularly required to work in those environments". Smoking also tends to increase blood cholesterol levels. Furthermore, the ratio of high-density lipoprotein (HDL, commonly referred to as "good" cholesterol) to low-density lipoprotein (LDL, "bad" cholesterol) tends to be lower in smokers compared to non-smokers. Smoking also raises the levels of fibrinogen and increases platelet production (both involved in blood clotting), which makes the blood thicker and more likely to clot. Carbon monoxide binds to hemoglobin (the component carrying the oxygen in red blood cells), resulting in a much more stable complex than hemoglobin bound with oxygen or carbon dioxide and therefore permanent loss of blood cell functionality. Blood cells are naturally recycled after a certain period, allowing for the creation of new, functional red blood cells. However, if carbon monoxide exposure reaches a certain point before it can be recycled, hypoxia (and later death) occurs. All these factors make smokers more at risk of developing various forms of arteriosclerosis (hardening of the arteries).
The exiled mayor of occupied Melitopol, Ivan Fedorov reported an explosion in the city center which led to outages in water, telecommunications and electricity in the eastern and northern districts of the city as well as surrounding villages; pro-Russian authorities confirmed the explosion and the power outage. Novaya Gazeta reported that an improvised explosive device was planted in a rubbish bin near an apartment block where the Russian-installed acting "deputy minister" of construction and public utilities lived, which exploded and injured him when he exited the building.
2 O−2 + 2 H+ → O2 + H2O2 2 H2O2 → O2 + 2 H2O Peroxisomes are organelles found in virtually all eukaryotic cells. They are involved in the catabolism of very long chain fatty acids, branched chain fatty acids, D-amino acids, polyamines, and biosynthesis of plasmalogens and ether phospholipids, which are found in mammalian brains and lungs. They produce hydrogen peroxide in a process catalyzed by flavin adenine dinucleotide (FAD):
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.